SciClone Pharma prices HK$2.2bn IPO at top end

Jonathan Breen

February 25, 2021 10:15 am

SciClone Pharmaceuticals bagged HK$2.18bn ($281.2m) after pricing its IPO high on the back of storming demand from institutional and retail investors, according to sources close to the deal.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

Nomura Credit Suisse Equity IPOs Equity China China International Capital Corp Hong Kong SAR Asia Greater China Morgan Stanley Northeast Asia Asia Pacific Emerging Markets

JB

Jonathan Breen

Equities editor GlobalCapital Asia